Plans are in place for a Guardant360-based assay to predict response to AsztraZeneca's Tagrisso and for a blood-based TMB test using the larger GuardantOmni panel.
The firm is seeking damages and various injunctions, citing 11 different counts of fraud, breach of contract, tortious interference, and unfair competition.
Research continues to show that it is possible to detect genetic signs of cancer in a blood sample without the need to measure specific oncogenic mutations.
Each share comes with an accompanying warrant to purchase one share of common stock. Biocept expects to use proceeds to fund ongoing operations.
The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.
A genomic analysis of modern and ancient maize reveals a complicated domestication history, according to Reuters.
In PLOS this week: MYRF variant linked to congenital diaphragmatic hernia, analysis of the "dragon's blood" red resin produced by traditional medicine plants, and more.
CNBC reports that half of academic researchers leave after about five years.
Researchers have used genetic analysis to confirm a new type of salamander, the New York Times reports.